Alexion Pharmaceuticals (ALXN) Price Target Increased to $175.00 by Analysts at Morgan Stanley

Alexion Pharmaceuticals (NASDAQ:ALXN) had its target price upped by Morgan Stanley from $165.00 to $175.00 in a research report report published on Tuesday morning. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

ALXN has been the subject of several other reports. BidaskClub lowered Alexion Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, February 7th. Credit Suisse Group reiterated a buy rating and issued a $156.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday, December 21st. Zacks Investment Research upgraded Alexion Pharmaceuticals from a hold rating to a strong-buy rating and set a $134.00 target price for the company in a research note on Tuesday, October 30th. Raymond James reissued a buy rating on shares of Alexion Pharmaceuticals in a research report on Sunday, December 30th. Finally, ValuEngine raised Alexion Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, November 8th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Alexion Pharmaceuticals has an average rating of Buy and a consensus price target of $162.33.

Alexion Pharmaceuticals stock opened at $124.26 on Tuesday. The firm has a market capitalization of $26.85 billion, a P/E ratio of 17.53, a price-to-earnings-growth ratio of 0.89 and a beta of 1.56. Alexion Pharmaceuticals has a 52 week low of $92.56 and a 52 week high of $140.77. The company has a quick ratio of 2.48, a current ratio of 2.88 and a debt-to-equity ratio of 0.31.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Monday, February 4th. The biopharmaceutical company reported $2.14 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.60 by $0.54. The firm had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.06 billion. Alexion Pharmaceuticals had a return on equity of 18.15% and a net margin of 1.88%. The business’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.48 earnings per share. Research analysts predict that Alexion Pharmaceuticals will post 8.51 EPS for the current year.

In other news, EVP Indrani Lall Franchini sold 2,605 shares of the company’s stock in a transaction dated Wednesday, November 28th. The stock was sold at an average price of $118.13, for a total value of $307,728.65. Following the completion of the sale, the executive vice president now owns 29,304 shares of the company’s stock, valued at $3,461,681.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ludwig Hantson sold 3,244 shares of the company’s stock in a transaction dated Monday, December 31st. The stock was sold at an average price of $95.85, for a total value of $310,937.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,093 shares of company stock valued at $929,603. 4.35% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC boosted its position in shares of Alexion Pharmaceuticals by 8.1% in the third quarter. FMR LLC now owns 21,096,993 shares of the biopharmaceutical company’s stock worth $2,932,693,000 after buying an additional 1,581,376 shares during the period. BlackRock Inc. boosted its position in shares of Alexion Pharmaceuticals by 0.3% in the third quarter. BlackRock Inc. now owns 16,302,528 shares of the biopharmaceutical company’s stock worth $2,266,214,000 after buying an additional 41,943 shares during the period. Vanguard Group Inc. boosted its position in shares of Alexion Pharmaceuticals by 1.2% in the third quarter. Vanguard Group Inc. now owns 15,811,291 shares of the biopharmaceutical company’s stock worth $2,197,928,000 after buying an additional 192,857 shares during the period. Vanguard Group Inc boosted its position in shares of Alexion Pharmaceuticals by 1.2% in the third quarter. Vanguard Group Inc now owns 15,811,291 shares of the biopharmaceutical company’s stock worth $2,197,928,000 after buying an additional 192,857 shares during the period. Finally, Jennison Associates LLC boosted its position in shares of Alexion Pharmaceuticals by 1.2% in the fourth quarter. Jennison Associates LLC now owns 8,728,912 shares of the biopharmaceutical company’s stock worth $849,847,000 after buying an additional 101,376 shares during the period. 94.20% of the stock is owned by institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Story: Outstanding Shares and The Effect on Share Price

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit